Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Novavax announces fresh round of layoffs to rein in costs

Published 01/31/2024, 08:15 AM
Updated 01/31/2024, 12:01 PM
© Reuters. FILE PHOTO: Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) -COVID-19 vaccine maker Novavax (NASDAQ:NVAX) said on Wednesday it will reduce about 12% of its total workforce as the cash-strapped biotech company seeks to further cut costs amid doubts about its ability to remain in business.

The Maryland-based company had said in May it would cut a quarter of its workforce, just months after its "going concern warning". Since then, Novavax has been eyeing further cost cuts as it focuses on its updated COVID shot and the development of its COVID and flu combination vaccine.

About 30% of full-time jobs would be impacted by both the layoff rounds, the company said in an email response. The vaccine maker had 1,992 full-time employees as of Feb. 21, 2023, according to the latest annual regulatory filing.

Novavax said the decision is part of its intention to bring down expenses below $750 million this year, which it had disclosed during its third-quarter earnings call in November.

© Reuters. FILE PHOTO: Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Novavax sees the full annual impact of the cost savings to be realized in 2025, and expects to incur one-time charges of about $4 million to $7 million in the first quarter of 2024.

Shares of the biotech rose nearly 2% to $4.10.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.